Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology.
Saved in:
| Title: | Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology. |
|---|---|
| Authors: | Reis-Filho JS; Cancer Biomarker Development, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA., Scaltriti M; Translational Medicine, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA., Kapil A; Oncology Research and Development, AstraZeneca Computational Pathology GmbH, AstraZeneca, Munich, Germany., Sade H; Oncology Research and Development, AstraZeneca Computational Pathology GmbH, AstraZeneca, Munich, Germany., Galbraith S; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland, USA. |
| Source: | Molecular oncology [Mol Oncol] 2024 Nov; Vol. 18 (11), pp. 2607-2611. Date of Electronic Publication: 2024 Aug 30. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.13724 |
